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Lipoxygenases are critical enzymes in the biosyn-
thesis of families of bioactive lipids including com-
poundswith important roles in the initiation and reso-
lution of inflammation and in associated diseases
such as diabetes, cardiovascular disease, and
cancer. Crystals diffracting to high resolution (1.9 A˚)
were obtained for a complex between the catalytic
domain of leukocyte 12-lipoxygenase and the iso-
form-specific inhibitor, 4-(2-oxapentadeca-4-yne)
phenylpropanoic acid (OPP). In the three-dimen-
sional structure of the complex, the inhibitor occu-
pied a new U-shaped channel open at one end to
the surface of the protein and extending past the
redox-active iron site that is essential for catalysis.
In models, the channel accommodated arachidonic
acid, defining the binding site for the substrate of
the catalyzed reaction. There was a void adjacent
to the OPP binding site connecting to the surface of
the enzyme and providing a plausible access channel
for the other substrate, oxygen.
INTRODUCTION
Polyunsaturated fatty acid metabolism culminates in the forma-
tion of numerous bioactive lipids, the eicosanoids, with specific
roles in the inflammatory process (Funk, 2001). Prostaglandins
and thromboxanes stem from the cyclooxygenase-initiated
branch, whereas leukotrienes, lipoxins, HETEs, and other
compounds are formed by lipoxygenase-inaugurated events.
The ultimate pattern of these metabolites has important conse-
quences for human health and disease. Lipoxygenases catalyze
the oxygenation of arachidonic acid in both a regiospecific and
a stereospecific fashion, producing hydroperoxide products
primarily at the 5-, 8-, 12-, and 15- positions (Brash, 1999). The
catalyzed reaction requires the redox participation of nonheme
iron (Funk et al., 1990b). The various isoenzymes are not only
position specific, but also species, tissue, and cell specific,
making themdifficult to target with inhibitors. It might be possible
to design specific inhibitors, but there have been few structural
studies of mammalian lipoxygenases that would reveal differ-
ences that could be exploited for this purpose. There are1490 Structure 20, 1490–1497, September 5, 2012 ª2012 Elsevier Ltcurrently only two examples of mammalian lipoxygenase for
which three-dimensional structures were determined.
The three-dimensional structure for a complex between rabbit
reticulocyte 15-lipoxygenase and an inhibitor was first published
in 1997 (Gillmor et al., 1997). A subsequent analysis of the orig-
inal X-ray diffraction data led to publication of a more detailed
description of the structure in 2008 (Choi et al., 2008). Very
recently, the structure of a stabilized human 5-lipoxygenase
was reported in the absence of any ligand (Gilbert et al., 2011).
Crystallographically determined structures for lipoxygenases
from soybeans and coral have also been published (Minor
et al., 1996; Skrzypczak-Jankun et al., 1997; Neau et al., 2009).
The lipoxygenases all consist of two domains, a smaller
N-terminal b-barrel, known as a membrane-associating C2
domain, and a larger C-terminal domain composed for the most
part of long a-helixes, and containing the redox-active iron
necessary for the catalyzed reaction. A substantial body of
knowledge concerning lipoxygenase catalysis has also been
published, based on molecular manipulations, kinetics, and
spectroscopic studies of specific isoenzymes (Ivanov et al.,
2010; Nagel and Klinman, 2006; Gaffney, 1996). However, since
1997, there has been no new structural information regarding
ligand-binding for this important class of enzymes. For example,
there is no structural basis for something as fundamentally
important as how the substrate binds.
Classifying the lipoxygenase sequences is a challenge,
because the isoenzymes can be both species and cell-type
specific. Porcine leukocyte 12-lipoxygenase, the subject of the
research in this report, is more like human leukocyte 15-lipoxy-
genase (Sigal et al., 1988) (86% identical) and rabbit reticulocyte
15-lipoxygenase (O’Prey et al., 1989) (79% identical) than human
platelet 12-lipoxygenase (Funk et al., 1990a) (66% identical) or
human 5-lipoxygenase (Dixon et al., 1988) (41% identical).
Because the reticulocyte and leukocyte 12- and 15-lipoxyge-
nases have closely related sequences and catalytic behavior,
producing similar ratios of 12- and 15-hydroperoxides under
comparable conditions, these isoenzymes are sometimes
referred to as 12/15-lipoxygenases (Dobrian et al., 2011). The
porcine leukocyte enzyme was first isolated and later cloned
for expression in yeast, insect cells, and ultimately E. coli
(Yokoyama et al., 1986; Reddy et al., 1994a, 1994b; Richards
andMarnett, 1997; Rapp et al., 2009). A class of isoform-specific
inhibitors was discovered for this 12-lipoxygenase, which led to
a thorough kinetic analysis of the effect of 4-(2-oxapentadeca-4-
yne)phenylpropanoic acid (OPP) on catalysis (Gorins et al., 1996;d All rights reserved
Table 1. Data Collection and Refinement Statistics
12-Lipoxygenase Catalytic-Domain-Inhibitor
Complex
Data Collection
Space group P21
Cell dimensions
a, b, c (A˚) 83.45, 181.54, 91.61
a, b, g () 90.00, 92.86, 90.00
Resolution (A˚) 48.97–1.89 (1.99–1.89)a
Rmerge 0.098 (0.284)
I/sI 9.0 (3.8)
Completeness (%) 99.5 (98.3)
Redundancy 3.6 (3.4)
Refinement
Resolution (A˚) 48.97–1.89 (1.94–1.89)
No. unique reflections 214717 (15209)
Rwork/Rfree 0.17/0.21 (0.21/0.25)
No. atoms 18964
Protein 17580
Ligand 104
Solvent 1276
Fe 4
B-factors 22.42
Protein 22.15
Ligands 20.41
Solvent 26.40
Fe 11.86
RMSDs
Bond lengths (A˚) 0.026
Bond angles () 1.974
Values in parentheses are for the highest-resolution shell. See also
Figure S1.
aNumber of crystals = 1.
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Lipoxygenase-Inhibitor Complex Crystal StructureRichards, et al., 1999; Moody and Marnett, 2002). The results
showed that the compound bound to the free (both Fe[II] and
Fe[III]) form of the enzyme and the substrate-bound form, all
with high affinity.
Crystallization experiments on the mammalian lipoxygenases
were previously hampered by an inherent flexibility in the protein.
The working hypothesis for the basis for this effect is that the two
domains can adopt numerous conformations in solution relative
to one another, ranging from closely associated compact struc-
tures tominimally associated extended conformations. Evidence
for the existence of this degree of flexibility was found in small-
angle X-ray scattering measurements on several mammalian lip-
oxygenases (Shang et al., 2011). The effect was also manifest for
leukocyte 5-lipoxygenase, for which crystallization was only real-
ized with a version of the protein modified to stabilize a compact
configuration (Gilbert et al., 2011). The successful strategy adop-
ted here was to truncate the N-terminal C2 b-barrel domain alto-
gether, and investigate the crystallization behavior of the iron-
containing C-terminal domain. There have been several previous
reports on truncated lipoxygenases, the mini-LOXs, but those
constructs tended to have limited stability and were not crystal-
lized (Maccarrone et al., 2004; Walther et al., 2002). A C-terminal
domain for porcine leukocyte 12-lipoxygenase was discovered
that retained catalytic activity. Crystals for this protein were ob-
tained, but only in the presence of the isoform-specific inhibitor,
OPP. The crystals diffracted X-rays to high resolution, affording
a three-dimensional structure for a complex providing numerous
insights into substrate binding and catalysis. The position of the
inhibitor in the complex adjacent to the redox-active iron cofactor
identified the first substrate-binding site for any lipoxygenase.
There was a void connected to the surface of the enzyme
providing oxygen access to the site of catalysis. The structure
of the complex provides a basis for understanding the regio-
and stereoselectivity of the catalyzed reaction, the structure-
function behavior of inhibitors, and the results of numerous
molecular manipulations previously conducted on the enzyme.
RESULTS AND DISCUSSION
The Catalytic Domain of 12-Lipoxygenase Formed
Crystals with OPP that Diffracted X-Rays to High
Resolution
Sparse matrix screening of crystallization conditions did not
produce diffraction-quality crystals for full-length 12-lipoxyge-
nase or the protein containing any of numerous molecular modi-
fications to amino acids (potentially exposed Cys residues) or
clusters of amino acids (surface entropy reduction) carried out
to enhance crystallization. Altogether, at least 10,000 trials were
performed. The C-terminal domain (residues 112–663) cloned
and expressed in E. coli was catalytically active and reasonably
stable. A version of the catalytic domain containing an N-terminal
six His-tag and serines substituting for cysteines at positions 210
and 292 was screened for crystallization in the presence and
absence of the isoform-specific inhibitor, OPP. Incubation of
the modified 12-lipoxygenase catalytic domain with solid OPP
followed by exposure to 10% PEG 20,000 in 0.1 M MES buffer
at pH 6.5 containing 20% glycerol resulted in crystals of
a complex. While the crystallization occurred consistently under
carefully controlled conditions, the omission of any aspect ofStructure 20, 1490–14the protocol resulted in no crystallization. For example, there
was a thrombin cleavage site engineered to allow for removal of
the N-terminal six His-tag. The protein devoid of the tag did not
crystallize under any conditions. Most importantly, no crystalliza-
tion was ever observed in the absence of the inhibitor.
Large crystals were obtained from the optimized crystalli-
zation conditions, but these were invariably multiples that
produced overlapping diffraction patterns. Small crystals irradi-
ated through a 20 mm beam collimator on ID-D of the LS-CAT at
the Advanced Photon Source provided single-crystal X-ray
diffraction patterns extending to 1.9 A˚ resolution. The structure
was determined by the molecular replacement method using
the revised structure of 15-lipoxygenase (PDB ID 2P0M) for the
starting model. Data collection and refinement values are
collected in Table 1.
The Inhibitor Was Located in a U-Shaped Channel Open
on One End to the Protein Surface
The isoenzyme-specific inhibitor, OPP, was found in all four
monomers of the protein in the asymmetric unit. In the structure97, September 5, 2012 ª2012 Elsevier Ltd All rights reserved 1491
Figure 1. Location of the OPP Binding Site
in Complex with the 12-Lipoxygenase Cata-
lytic Domain
(A) A semitransparent surface representation of
the catalytic domain indicates where OPP was
found in the 2Fo-Fc map of the catalytic domain.
The position of the N-terminal domain modeled
from the structure of 15-lipoxygenase is presented
in cartoon representation. The helix represents the
position of helix a2.
(B) A cutaway surface representation shows the
2Fo-Fc map and the structure of OPP. The
spheres indicate the positions of the iron atom and
the iron-associated water/hydroxide. The 2Fo-Fc
maps were contoured at 1.5 s.
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12-lipoxygenase in a U-shaped channel adjacent to the
nonheme iron site that was open at one end to the surface of
the protein (Figure 1). The carboxylate of the inhibitor formed
hydrogen-bonding interactions with Gln-596 at the opening of
the channel (Figure 2). Arg-403 was close by, but three water
molecules mediate the interaction with the inhibitor. In addition,
the occupancies of the carboxylate groups for the OPPs were
refined to be 0.5, suggesting that the orientation could be flexible
except for the presence of this one dominant conformation.
Otherwise, the contacts between OPP and the protein were all
hydrophobic interactions. For example, Leu-179 was located in
the channel opening in a position to facilitate the penetration of
the hydrophobic inhibitor. Gly-407 and Leu-597 extended this
hydrophobic surface into the channel. Phe-175 was perpendic-
ular to the aromatic ring of the inhibitor and at a distance of
3.2 A˚ was in a position to form a CH-p interaction (Brandl
et al., 2001). Ile-400, Leu-408, Ala-404, Ile-593, and Ile-663
were interacting with C10–C15 of OPP. The inhibitor-binding
site was terminated in a pocket of hydrophobic residues
including Phe-353, Val-418, Val-419, Phe-415, and Ile-414
(Figure 2).
Arachidonic acid was modeled into the electron density for
OPP in the 2Fo-Fc map, illustrating that the U-shaped channel
could serve as the substrate-binding site. The position of arach-
idonic acid generated in this way is illustrated in Figure 3. In this
model, C10 was the closest substrate carbon to Fe-OH with
a C-to-O distance of 2.9 A˚. The distance from C10-H to FeOH-O
would be on the order of only 1.8 A˚. Kinetic isotope studies pre-
dicted a very short distance for the H-atom abstraction reaction
for lipoxygenases (Nagel and Klinman, 2006). The orientation of1492 Structure 20, 1490–1497, September 5, 2012 ª2012 Elsevier Ltthe arachidonic acid molecule in the model was also consistent
with the stereochemical outcome for the catalyzed reaction. If
hydrogen-atom abstraction at C10 took place from the back,
to be consistent with the location of the FeOH, and the oxygen
molecule reacted at C12 from the front, as arachidonic acid is
oriented in the figure, the result would be the formation of the
observed 12(S)-hydroperoxide.
An Internal Void in the Structure of 12-Lipoxygenase
Provides a Path for Oxygen from the Surface to the
Active Site
The orientation for the addition of oxygen described in the
previous section is consistent with the presence of an extended
void in the structure from the nonheme iron site to the surface of
the protein that intersects the substrate channel, providing
a plausible dioxygen pathway for lipoxygenase catalysis (Fig-
ure 4). This channel has an amphiphilic character, with hydro-
philic amino acid side chains close to the surface and hydro-
phobic side chains close to the active site. This distribution
may facilitate the movement of oxygen along the channel to
the substrate-binding site. Two amino acids, Leu-367 and Ala-
404, have been implicated in the delivery of oxygen to the
nonheme iron site. Modification of the leucine at position 367
to phenylalanine led to an increase in KM for oxygen in rate
measurements on the rabbit reticulocyte 15-lipoxygenase-cata-
lyzed reaction (Saam et al., 2007). The structure confirms the
hypothesis that this amino acid side chain lies in a catalytically
relevant path for the oxygen molecule to the active site. The
stereochemistry and regiochemistry of the lipoxygenase-cata-
lyzed reaction was sensitive to the presence of alanine (versus
glycine) at position 404 (Coffa and Brash, 2004). The hypothesisFigure 2. Specific Interactions between
OPP and the 12-Lipoxygenase Catalytic
Domain
A stereodiagram representing the amino acid side
chains interacting with OPP.
d All rights reserved
Figure 3. The Substrate-Binding Site in Leukocyte 12-Lipoxygenase
Arachidonic acid modeled in place of the inhibitor, OPP, indicates the likely
orientation for the substrate leading to catalysis.
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approach of oxygen toward one end of the pentadienyl radical
intermediate, e.g., the 8-position, enforcing the observed
stereochemical outcome, S, at the 12-position. The model of
the three-dimensional structure including arachidonic acid
shows that Ala-404 is immediately adjacent to the 8-position of
the substrate, blocking the access of the proposed oxygen
channel to C8, as proposed.
The Iron Site in 12-Lipoxygenase Was a Well-Organized
Octahedral Ligand Field
The redox-active, nonheme iron atom in 12-lipoxygenase was
coordinated by four histidines (His-361, His-366, His-541, and
His-545), the main chain carboxylate from the C terminus
(Ile-663), and one water/hydroxide in a pseudo-octahedral con-
figuration (Figure 5). The coordinated water molecule was also
stabilized by a hydrogen bond with the nonligated oxygen
atom (O2) of the terminal carboxylate. This additional bonding re-
sulted in small B-factors for the water molecules (9, 12, 18, andStructure 20, 1490–1413 A˚2 for the four chains A–D in the asymmetric unit) that were
comparable in magnitude to the B-factors of their bonded iron
atoms (9, 9, 17, and 12 A˚2, respectively). The iron-ligand
distances in the crystal structure, which averaged 2.23 ±
0.06 A˚, are collected in Table 2 along with values for comparison
from 5-lipoxygenase and 15-lipoxygenase. The triple bond of the
inhibitor was adjacent to the nonheme site at a distance of
roughly 4 A˚ from the iron. The metal-ligated water molecule
was on the channel surface at a distance of 3.05 A˚ from the triple
bond.
The iron site in the 12-lipoxygenase catalytic domain was
more ordered than the iron sites in 5- or 15-lipoxygenase. For
example, in 5-lipoxygenase, a water molecule was not as tightly
coordinated to the iron and was not in a position to be as effec-
tively stabilized by hydrogen bonding to theC-terminal Ile, result-
ing in a B-factor of 36 in one of the monomers in the structural
model. No water molecule at all was observed in the nonheme
iron site of the second monomer in the 5-lipoxygenase structure
or in the structure of 15-lipoxygenase (Choi et al., 2008; Gilbert
et al., 2011). Further, the iron-binding site in 12-lipoxygenase
had a distorted octahedral geometry, but significantly less dis-
torted than in the previously reported structures. The average
deviation from ideal octahedral geometry for the ligand-iron-
ligand angles was 4.5, roughly half the value observed in other
structures. What is most striking about the structures of the iron
sites in the various lipoxygenases is how different they can be.
This trend reinforces the notion that flexibility or mobility of the
iron and its coordination sphere represents an aspect of the
structure that is relevant to catalysis (Vahedi-Faridi et al., 2004).
The 12-lipoxygenase-OPP structure also clearly illustrates that
the substrate-to-iron distance can be very short. This is consis-
tent with the working hypothesis for the mechanism of the cata-
lyzed reaction, which includes H-atom tunneling that can only
take place over very short distances (Nagel and Klinman, 2006).
The Induced-Fit Mechanism for Binding of Inhibitor
Does Not Apply to Porcine Leukocyte 12-Lipoxygenase
The three-dimensional structure of the 12-lipoxygenase cata-
lytic domain was different from the structures of 5- and 15-
lipoxygenase (Choi et al., 2008; Gilbert et al., 2011) in an
important aspect, the position and conformation of the aminoFigure 4. Proposed Oxygen Access
Channel for 12-Lipoxygenase
A stereodiagram from the structural model with
arachidonic acid in the active site. Arachidonic
acid is depicted in a CPK representation (hydro-
gens omitted). The void adjacent to the substrate
binding channel is a semitransparent surface.
97, September 5, 2012 ª2012 Elsevier Ltd All rights reserved 1493
Figure 5. Comparison of the Iron Coordination Environments for the Mammalian Lipoxygenase
The iron environment in 12-lipoxygenase is much closer to a six coordinate octahedral geometry than in 5- or 15-lipoxygenase. Internuclear distances (dashed
lines) are provided in Table 2. The central spheres represent the iron atoms.
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Lipoxygenase-Inhibitor Complex Crystal Structureacids making up helix a2. A comparison of the mammalian
lipoxygenases in this region of their structures is presented
in Figure 6. The reevaluation of the original X-ray diffraction
data for rabbit 15-lipoxygenase concluded that the crystals
of the enzyme-inhibitor complex contained an open, apo
form and a closed form with the inhibitor present near the non-
heme iron site (Choi et al., 2008). The differences in the struc-
tures were primarily related to the position and conformation
of the amino acids that make up helix a2. The position of
this helix in the 12-lipoxygenase catalytic domain was much
more similar to the location in the open, apo structure of
15-lipoxygenase (Figure 6A) than to the inhibitor-bound closed
form (Figure 6B). The positions of these amino acids in the
5-lipoxygenase structure were quite distinctive (Gilbert et al.,
2011). They were found in a short, three-turn helix in a unique
orientation, flanked on both sides by extended loops (Fig-
ure 6C). The orange spheres in the figures represent the posi-
tions of the iron atoms, illustrating that these differences in
structure were in the portion of the protein covering the active
site. The interpretation for the presence of two conformations
in 15-lipoxygenase was an induced-fit mechanism for inhibitor
binding (Choi et al., 2008). The new structure of the 12-lipoxy-
genase catalytic domain indicated that a conformational
change of this kind was not a requirement for inhibitor binding,Table 2. Distances between Iron and Ligands in the Coordination
Spheres
12-LOX
5-LOX
(A)
5-LOX
(B)
15-LOX
(A)
15-LOX
(B)
Fe$$$His-361 2.1 2.2 2.2 2.2 2.6
Fe$$$His-366 2.2 2.1 2.3 2.4 2.1
Fe$$$His-541 2.1 2.2 2.1 2.4 2.3
Fe$$$His-545 2.3 3.2 3.2 2.3 2.6
Fe$$$Ile-663 2.3 2.2 2.2 2.2 2.0
Fe$$$H2O 2.2 3.6 None None None
H2O$$$Ile-663 2.5 3.0 None None None
Distances are given in A˚. The residue numbering corresponds to the
sequences of 12- and 15-lipoxygenase (LOX). The corresponding resi-
dues in 5-LOX are His-367, His-372, His-550, Asn-554, and Ile-673,
respectively. In both 5- and 15-LOX, there are two molecules (A and B)
in the asymmetric unit, with significant differences in the distances.
1494 Structure 20, 1490–1497, September 5, 2012 ª2012 Elsevier Ltbecause OPP was bound directly to the ‘‘open’’ conformation
of the protein.
The inhibitors in the structures of 12- and 15-lipoxygenases
adopted quite different orientations in their respective binding
sites. This was consistent with the fact that a significant confor-
mational change was necessary to account for inhibitor binding
to 15-lipoxygenase (Choi et al., 2008). A comparison of the orien-
tations of the two inhibitor molecules is provided in Figure 7.
Alignment of the two protein structures was conducted using
secondary structural elements. The OPP and U-shaped channelFigure 6. Comparison of the Positions of Helix a2 in Structures of the
Mammalian Lipoxygenases
In each panel, the position of the helix a2 in the 12-lipoxygenase-OPP complex
is in a roughly horizontal orientation, and the position of the iron atom is indi-
cated by a sphere.
(A) Open conformation: apo 15-lipoxygenase structure.
(B) Closed conformation: 15-lipoxygenase-RS75091 complex.
(C) 5-Lipoxygenase structure.
d All rights reserved
Figure 7. Differences in Inhibitor Binding to Leukocyte 12-Lipoxyge-
nase and Reticulocyte 15-Lipoxygenase
A comparison of the positions of OPP in the complex with 12-lipoxygenase in
approximately the same orientation as Figure 1B and RS75091 in the complex
with 15-lipoxygenase. The cutaway surface of 12-lipoxygenase is in semi-
transparent representation. The surface of 15-lipoxygenase is not shown for
clarity.
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shown in approximately the same orientation as in Figure 1B. The
relative position of RS75091 in the 15-lipoxygenase structure is
shown for comparison. In the structure of 15-lipoxygenase, the
inhibitor occupied a large, boot-shaped cavity that was not con-
nected to the surface of the protein. While OPP and RS75091
were both found close to the iron site, further similarities were
not evident. The common structural features of the inhibitors,
the carboxylate groups, aromatic rings, and hydrophobic tails,
were all found in completely different places in the two struc-
tures. The geometry enforced by the ortho substitution pattern
in RS75091 in all likelihood accounts for the different modes of
binding. For example, this feature would prevent entry to the
U-shaped channel by direct insertion. The structure of inhib-
itor-bound 15-lipoxygenase has been used as a starting point
in molecular modeling and docking studies for the purpose of
inhibitor discovery (Toledo et al., 2010). The structure of the
12-lipoxygenase complex will provide a template for such
studies based on amuchmoremechanistically relevant channel.
Further, the results with 12-lipoxygenase and OPP, compared to
15-lipoxygenase and RS75091, indicated that there may be
a structural basis for distinguishing between isoenzymes with
inhibitors.
The Structure of the Complex Is Informative Regarding
the Mode of Inhibition and the Mechanism of the
Catalyzed Reaction
OPP binds to both the Fe(III) and Fe(II) forms of leukocyte
12-lipoxygenase, but much more tightly to the Fe(II) form
(KIFe(II) = 70 nM; KIFe(III) = 2000 nM) (Moody and Marnett,
2002). The tight binding to the Fe(II) form accounts for OPP’s
mechanism of inhibition, which is preventing activation of the
enzyme by hydroperoxide-dependent oxidation of Fe(II) (inac-Structure 20, 1490–14tive) to Fe(III) (active) enzyme. This implies that the U-shaped
channel is also the site of fatty acid hydroperoxide binding,
because iron oxidation requires direct contact between the
metal center and the hydroperoxide group.
The structure of the boundOPP in the cavity fits beautifully with
the structure-activity relationship for inhibition (Gorins et al.,
1996). The number of carbons between the carboxylate of OPP
and the phenyl ring could be 0–2, but when it was increased to
3, inhibition was lost. The number of carbons between the phenyl
ring and the ether oxygen could only be one, and the alkyl group
could be C8–12, with C10 optimal. Inhibition was lost when the
alkyl group was C14. Although the presence of the alkyne
conferred optimal activity, allenes and trans olefins were nearly
as active, whereas cis olefins were much less active and satu-
rated hydrocarbons were inactive. Examination of the structure
of the OPP-12-lipoxygenase complex reveals that the alkyne is
positioned immediately adjacent to the nonheme iron, and the
phenyl-propionate and long-chain alkyl groups provide maximal
interactions between Gln-596 and the end of the U-shaped
cavity. Interestingly, 5,8,11,14-eicosatetraynoic acid, the tetra-
alkynyl analog of arachidonic acid, acts in a mechanistically
similar fashion to OPP by preventing hydroperoxide-dependent
activation of porcine leukocyte 12-lipoxygenase.
EXPERIMENTAL PROCEDURES
Construction of the Expression Plasmid
pET-20-C210SC292S was obtained with the QuikChange multi-site-directed
mutagenesis kit using primers 50-CAA CAG GAT TTT CTG GAG TGG CCA
GAG CAA GCT-30 and 50-GCC AAT GTC ATC CTG AGT AGC CAG CAG
TAC C-30. The cDNA of the lipoxygenase catalytic domain (residues 112–
663) was amplified by polymerase chain reaction using customized primers
50-GAG CCT CCA TAT GGG CAC TGC CCG CAC AGT G-30 and 50-CTG
GCT CGA GTC AGA TGG CCA CAC TGT TTT C-30, cleaved with NdeI and
XhoI, and then cloned into pET-28a via NdeI/XhoI restriction sites. The LCD
gene was transferred from pET-28-HLCDS to expression vector pET-20b-
HLCDS through XbaI/XhoI sites.
Expression and Purification of 12-Lipoxygenase Catalytic Domain
The pET-20b-HLCDS plasmids were transformed into Rosetta 2 (DE3) cells.
Freshly grown bacterial cultures (1 ml) from a single colony were first grown
for 4 hr in 100 ml Lysogeny Broth (LB) containing ampicillin (100 mg ml1)
and chloramphenicol (34 mg ml1) (OD600 1.2), and the entire culture was
combined with 1,000 ml Auto-induction Lysogeny Broth (Auto-LB) medium
(Studier, 2005) (10 g tryptone, 5 g yeast extract, 3.3 g (NH4)2SO4, 6.8 g
KH2PO4, 13.4 g Na2HPO4 7H2O, 0.5 g glucose, 2.0 g a-lactose, and 0.15 g
MgSO4) with ampicillin (100 mg ml
1) and chloramphenicol (34 mg ml1), and
the cells were incubated for 24 hr at 30C with shaking (200 rpm). The cells
were collected by centrifugation, resuspended in phosphate-buffered saline,
and collected again by centrifugation. The cells were opened by sonication
in 200 ml lysis buffer containing 10 mM TrisHCl, 1 mM TCEP, 60 mg ml1
chicken egg white type II-O trypsin inhibitor, 100 mg ml1 catalase, 20 mg
ml1 DNase I, pH 7.4, and 0.5 mg ml1 chicken egg white lysozyme, and the
supernatant of the lysate was obtained by ultracentrifugation at 33,000 g.
The supernatant was then loaded to a Ni-NTA column (bed volume 5 ml)
and washed with 100 mM TrisHCl (pH 7.5), 10 mM imidazole, and eluted
with 100 mM TrisHCl (pH 7.5), 200 mM imidazole. The elution was dialyzed
against 10 mM TrisHCl, 1 mM TCEP buffer overnight and further purified on
a Source 15Q (GE Life Science) anion exchange column using 0–40% gradient
of 10 mM TrisHCl, 1 M NaCl. The chromatographic procedures were conduct-
ed on an AKTA FPLC (Amersham Biosciences) operated at 4C. An enzymatic
assay was used to find the active fractions, and the purity of the isolated
protein was evaluated by SDS PAGE in 10% Bis-Tris mini gels (NuPAGE, Invi-
trogen) using MES SDS running buffer.97, September 5, 2012 ª2012 Elsevier Ltd All rights reserved 1495
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The maximum rate of the lipoxygenase-catalyzed reaction with arachidonic
acid as substrate was determined spectrophotometrically at 234 nm in 3 ml
of assay buffer (50 mM TrisHCl, 0.03% Tween-20 [pH 7.4]) at 25C, as previ-
ously described (Rapp et al., 2009). Arachidonic acid was dissolved in abso-
lute ethanol and was delivered by airtight 50 ml syringe. All final assay solutions
contained 1% ethanol (v/v). The specific activity for the catalytic domain was
1.55 ± 0.38 mmol mg1 min1 compared with 8.14 ± 0.59 mmol mg1 min1
for full-length 12-lipoxygenase prepared in the same fashion, or about 21%
on a per-molecule basis.Crystallization and Data Collection
Purified protein was concentrated to 6 mg/ml using Millipore Amicon 50 kDa
MWCO filtration devices and then incubated with solid OPP for 16 hr. This
solution was then further concentrated to 1113 mg/ml. Crystals were grown
by hanging-drop vapor diffusion method at 291 K by mixing 2 mL protein inhib-
itor and 2 ml reservoir solution containing 0.1 M MES (pH 6.5), 5%10% PEG-
20,000, 20% glycerol. The crystals were flash frozen for shipment and data
collection.Structure Determination
Diffraction data were collected at 100 K at LS-CAT beamline 21-ID-D
(l = 1.0781 A˚) at the Advanced Photon Source, Argonne, Illinois, using
a 20 mm beam collimator. Data were processed with iMosflm (Battye et al.,
2011) and reduced by SCALA (CCP4, 1994). Crystals belonged to space group
P21 (a = 83.450 A˚, b = 181.540 A˚, c = 91.610 A˚, and b = 92.86
). There were four
monomers in one asymmetric unit (Table 1). The rms deviations for the alpha
carbons in any two of the molecules ranged from 0.2188 to 0.3904 A˚. There
were no significant structural differences evident among the monomers. The
C-terminal part of rabbit 15-lipoxygenase structure (PDB ID 2P0M, residues
112–663 of chain A) was used as the search model. Molecular replacement
was performed with Phaser (McCoy et al., 2007). Mutations andmanual model
building were performed in COOT (Emsley et al., 2010). Refinement was
continued in REFMAC with rigid-body refinement and restrained refinement
(Potterton et al., 2003; Skuba´k et al., 2004). Noncrystallographic symmetry
was not applied during the refinement. The potential of phase bias was
excluded by simulated annealing. Ligand was built using SMILE and waters
were added from COOT (Emsley et al., 2010). The simulated annealing OMIT
maps were generated with Phenix (Adams et al., 2010). The void of the dioxy-
gen channel was calculated with a sphere size of 1.2 A˚ using the program
HOLLOW (Ho and Gruswitz, 2008). Ligand occupancy refinement was carried
out in Phenix (Adams et al., 2010). An example of the Fo-Fc electron density for
OPP is presented in Figure S1 available online. The final model has Rwork and
Rfree of 17.3 and 21.4, respectively (Table 1). The values of the Ramachandran
plot for the final refinement of the structure were obtained with PROCHECK
(92.3% most favored, 7.5% additional allowed, 0.2% generously allowed,
and 0% outliers) (Laskowski et al., 1993). The illustrations were prepared
with Pymol Molecular Graphics System, Version 1.3 (Schro¨dinger, LLC). All
of the figures contain representations of monomer A.SUPPLEMENTAL INFORMATION
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